HBG2 and sickle cell disease: In addition to gene editing therapy, base editing approaches for sickle cell disease are in clinical trials developed by Beam Therapeutics with two different therapeutic approaches in which BEAM‐101 targets HBG1 and HBG2 promoters to upregulate hemoglobin F, whereas BEAM‐102 swaps the harmful nucleotide substitution in the HBB gene for a naturally occurring, nonpathogenic mutation.